Geneva, June 22 -- International Clinical Trials Registry received information related to the study (NCT07645690) titled 'The Safety and Efficacy of Allogeneic CD70 CAR-T Therapy in Unresectable or Metastatic Clear Cell Renal Cell Carcinoma' on June 9.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Chinese PLA General Hospital
Condition:
Unresectable or Metastatic Clear Cell Renal Cell Carcinoma
Intervention:
Biological: CLEAR CAR-T cell injection
Recruitment Status: Recruiting
Phase: Early Phase 1
Date of First Enrollment: July 1, 2026
Target Sample Size: 30
Countries of Recruitment:
China
To ...